Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
XORTX Therapeutics Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
XRTX
Nasdaq
2834
www.xortx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for XORTX Therapeutics Inc.
XORTX Announces USD $925,000 Private Placement
- Jun 26th, 2025 5:00 am
XORTX Announces USD $3 Million Offering
- May 19th, 2025 5:00 am
XORTX Provides Update on FDA Type B Meeting Request
- Apr 30th, 2025 5:00 am
XORTX Announces Grant of European Patent
- Apr 28th, 2025 5:00 am
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Apr 17th, 2025 5:45 pm
XORTX Announces Update for Discussion with the FDA
- Mar 19th, 2025 5:00 am
XORTX Commences Gout Program NDA Discussions with the FDA
- Feb 24th, 2025 5:00 am
XORTX to Present at Microcap Conference
- Jan 29th, 2025 5:00 am
XORTX Announces Change of Auditor
- Jan 17th, 2025 3:00 pm
XORTX Adds Late Stage Gout Program to Pipeline
- Jan 6th, 2025 5:00 am
XORTX Strengthens Executive Team
- Dec 19th, 2024 5:00 am
XORTX Announces Presentation at the Rare and Genetic Disease Summit
- Dec 12th, 2024 7:17 am
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024
- Oct 24th, 2024 5:00 am
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
- Oct 18th, 2024 2:00 pm
XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
- Oct 17th, 2024 6:00 am
XORTX Initiates Precision Medicine Program
- Oct 9th, 2024 3:00 am
XORTX Announces Results of Annual and Special Meeting of Shareholders
- Sep 13th, 2024 5:00 am
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A
- Sep 12th, 2024 3:30 pm
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
- Sep 6th, 2024 3:30 pm
Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
- Sep 3rd, 2024 10:30 am
Scroll